Testicular Neoplasms
21
2
3
12
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
19.0%
4 terminated out of 21 trials
75.0%
-11.5% vs benchmark
5%
1 trials in Phase 3/4
17%
2 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (21)
Lymphedema After Urologic Surgery
Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
Role of Axumin PET Scan in Germ Cell Tumor
A Study of SGN-ALPV in Advanced Solid Tumors
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
Effect of Online Education Given to Young Adults on Testicular Cancer Health Beliefs and Behaviors
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours
The Platinum Study Comparison Group
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Avelumab in Refractory Testicular Germ Cell Cancer.
Engagement of Patients With Advanced Cancer
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy
Quality of Life Among Testicular Cancer Survivors
High-Intensity Aerobic Interval Training in Testicular Cancer Survivors
Testicular Cancer and Aerobic and Strength Training
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II